Gastrointestinal

The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
What are you going to recommend for a customer who was unable to complete a previously recommended regimen?
[[thumbnail_alt_text]]
In a series of studies, researchers described the identification of predictive tools and a new understanding of environmental factors that trigger inflammatory bowel disease.
[[thumbnail_alt_text]]
The goal of therapy centers on improving quality of life, maintaining remission, and preventing hospitalization and surgery.
[[thumbnail_alt_text]]
How can this patient better tolerate polyethylene glycol (PEG)-electrolyte lavage solution?
[[thumbnail_alt_text]]
FIRST Omeprazole Kits offer a pre-measured option for pharmacists dispensing suspended Omeprazole.
 
[[thumbnail_alt_text]]
Tofacitinib, currently used to treat rheumatoid arthritis and ulcerative colitis, has a correcting effect on defects that occur in inflammation.
[[thumbnail_alt_text]]
Shared insight on the open dialogues that should take place between patients with opioid-induced constipation and care providers.
[[thumbnail_alt_text]]
Key opinion leaders provide their perspectives on the goals of therapy and prophylactic management of opioid-induced constipation.
[[thumbnail_alt_text]]
A comprehensive review of opioid-induced constipation diagnosis strategies and foundational treatment guidelines.
[[thumbnail_alt_text]]
A panel of experts considers the disease pathology of opioid-induced constipation and the burden it has on patients.
[[thumbnail_alt_text]]
After some lots of ranitidine were found to contain small amounts of N-nitrosodimethylamine (NDMA), Novartis's Sandoz unit has announced that they are halting distribution of ranitidine (Zantac) products until the contamination concerns are resolved.
[[thumbnail_alt_text]]
Officials from the FDA have announced an approved package size and package type limit for over-the-counter (OTC) brand-name tablet and capsule forms of loperamide.